Receive regular headline summaries whenever high-quality news is generated for this page. We'll never share your email address with others.
|9/19/2022||Autosomal Dominant Polycystic Kidney Disease Market to Surge at a Significant CAGR of 14.5% by 2032 | DelveInsight
... analysis, the total ADPKD diagnosed prevalent cases in the 7MM were approximately 367K in 2021. Leading ADPKD companies such as Galapagos NV, Reata Pharmaceuticals, Kadmon Pharmaceuticals, Sanofi, Anakuria Therapeutics, Regulus Therapeutics, AceLink Therapeutics, Healx, XORTX Therapeutics, Poxel, Alebund Pharmaceuticals, Chinook Therapeutics, and others are developing novel ADPKD drugs that can ...
|9/13/2022||Reviewing Ovid Therapeutics (NASDAQ:OVID) and BriaCell Therapeutics (NASDAQ:BCTX)
... a short hairpin RNA gene therapy for the treatment of angelman syndrome; and OV815 for the treatment of kinesin-family of proteins associated neurological disorder. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, and Northwestern University, as well as Marinus Pharmaceuticals, Inc. The ...
|8/13/2022||Andrew Watson, Vice President of AI and R & D at Healx - Interview Series - New York Tech Media
Andrew Watson is Vice President of AI and R & D at Healx. Prior to joining Healx he worked at the technology giant Dyson, where he was the founding member of the Machine Learning Research Department, leading the research and implementation of machine learning and artificial intelligence across a variety of ...
|8/9/2022||England's Rare Diseases Action Plan Needs AI To Succeed
Dr. Tim Guilliams, co-founder and CEO of Healx , is an advocate for harnessing the power of AI to accelerate treatments for rare diseases. Rare diseases are largely overlooked by pharmaceutical companies and traditional drug discovery methods, despite the fact that 1 in 17 people in the UK will be ...
|6/6/2022||Global Drug Discovery Software Market valued at $2 billion in 2020, is poised to grow at a decent CAGR of 14% to reach $3.5 billion by 2025
... CROs. Competitive Landscape Analysis: Drug Discovery Software Market The global drug discovery software market is highly competitive and fragmented. Some of the top market players include Dassault Syst√®mes, LabVantage, PerkinElmer, Schrodinger, Abbott, Healx, Optibrium, Instem, Chemical Computing Group, dotmatics, idbs, Titian, Biovia, Celsius, Genome Biologics, Atomwise, Standigm, insitro, and ...
|3/21/2022||Healx Co-Founder and CEO Tim Guilliams will speak at the EU-Startups Summit in Barcelona on May 12-13!||eu-startups.com|
|3/11/2022||Founder in Five: Q&A with Healx CEO Tim Guilliams||uktech.news|
|3/2/2022||How Healx uses AI to transform rare disease drug discovery [PODCAST]||clarivate.com|
|2/25/2022||Gaboxadol in Combo Therapy for Fragile X Worth Pursuing: Healx||fragilexnewstoday.com|
|2/8/2022||Healx and Ovid Enter Strategic Partnership on Fragile X Syndrome Therapy||globalgenes.org|
|2/8/2022||Ovid pens deal to offload twice-failed former lead program, positioning Healx to write new chapter in fragile X||FierceBiotech|
|2/8/2022||Healx and Ovid Therapeutics to Enter Strategic Partnership||Globe Newswire|
|2/8/2022||Healx and Ovid Therapeutics Partner on Fragile X Therapy||pharmalive.com|
|2/8/2022||Healx and Ovid Therapeutics to Enter Strategic Partnership | Insider Tracking||insidertracking.com|
|2/8/2022||Ovid and Healx Enter Partnership to Develop Fragile X Treatment||Inside Precision Medicine|
|2/8/2022||Ovid Therapeutics & Healx to Enter Strategic Partnership||drug-dev.com|
|2/8/2022||Healx and Ovid Therapeutics to Enter Strategic Partnership||forextv.com|
|10/20/2021||UK startup Healx to begin clinical trial on repositioned drug for Fragile X syndrome||TechCrunch|
|10/20/2021||Clinical Trials Expand For AI-Designed Drug To Treat Fragile X Syndrome||Forbes|
|8/10/2021||Healx Enters Partnership with Ono Pharmaceutical to Repurpose Drugs for Rare Diseases||globalgenes.org|
|8/5/2021||Healx partners with Ono Pharmaceutical to expand AI capabilities for rare diseases||epmmagazine.com|
|4/9/2021||Healx launches partnership with Ataxia UK and FARA to find treatments for rare neurodegenerative condition||FirstWord PHARMA|
|4/8/2021||Healx partners with Ataxia UK and FARA to find treatments for Friedreich's ataxia||drugdiscoverytoday.com|
|1/13/2021||Healx teams up with Mission: Cure to discover and advance the world's first treatments for chronic pancreatitis||drugdiscoverytoday.com|
|8/25/2020||Global Rare Neurological Disease Treatment Market (2020 to 2027) - Analysis and Forecasts||PR Newswire|